Summary. 2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk.

Abecma is used to treat multiple myeloma in adults in certain situations. Specifically, it’s used to treat multiple myeloma that either: has returned after it was treated successfully before, or ...

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...

ABECMA INTERACTION WITH CANNABIS OR CBD. Cannabis (often called marijuana) and cannabis products, such as cannabidiol (CBD), have not been specifically reported to interact with Abecma.

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens.

2seventy bio has taken a new strategic route, narrowing its focus squarely on ABECMA, their CAR-T cell therapy developed in collaboration with Bristol Myers Squibb ().The company's Q4 earnings ...

For its part, Abecma made $89 million in the second quarter, up 36% on the previous quarter with the increase driven by "expanded capacity and vector supply," according to BMS.

Major players operating in the abecma market are Bristol-Myers Squibb. North America was the largest region in the abecma market in 2024. The regions covered in abecma report are Asia-Pacific ...

Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy. The decision to discontinue enrollment in the KarMMa-9 study was taken by TSVT and BMY ...

ABECMA REMS: Due to the risk of CRS and neurologic toxicities, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.

In other recent news, 2seventy bio has reported substantial growth in its third quarter of 2024, with U.S. revenues for its ...

Abecma generated U.S. revenue of $242 million in 2024, within 2seventy’s earlier-issued guidance to investors of between $240 million and $250 million.